HealthCare Royalty Announces Royalty Monetization Agreement for Modeyso® Commercial Royalties
Businesswire·2026-04-23 03:26
公司与交易 - HealthCare Royalty与代表前Oncoceutics Inc证券持有者的咨询集团达成了一项版税货币化协议，协议涉及Modeyso® (dordaviprone)商业销售版税的未披露百分比[1] - Modeyso® (dordaviprone)于2025年8月获得美国FDA加速批准，用于治疗1岁及以上、携带H3 K27M突变的弥漫性中线胶质瘤的成人和儿科患者[1]